SARS-CoV-2 surveillance testing and isolation management of immunocompromised patients: Survey results from 13 health care centers in the United States
As a newly emerging pathogen, infection prevention and isolation management response for SARS-CoV-2 varied greatly by individual health care center. Specific patient population needs, especially those of severely immunocompromised oncologic patients, potentially intensified the response. A survey wa...
Gespeichert in:
| Veröffentlicht in: | American journal of infection control 2024-12, Vol.52 (12), p.1463-1465 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1465 |
|---|---|
| container_issue | 12 |
| container_start_page | 1463 |
| container_title | American journal of infection control |
| container_volume | 52 |
| creator | Aslam, Anoshé Kamboj, Mini Bubb, Tania |
| description | As a newly emerging pathogen, infection prevention and isolation management response for SARS-CoV-2 varied greatly by individual health care center. Specific patient population needs, especially those of severely immunocompromised oncologic patients, potentially intensified the response. A survey was distributed to academic health care centers to ascertain surveillance testing frequency, patient placement, and isolation management for patients undergoing cell therapy treatments.
•Current SARS-CoV-2 guidance lacks information for patients receiving HCTs.•A survey sent to 13 transplant centers revealed heterogeneity in application of guidance.•Despite differences, transmission events were not reported. |
| doi_str_mv | 10.1016/j.ajic.2024.07.010 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3084772177</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0196655324006102</els_id><sourcerecordid>3084772177</sourcerecordid><originalsourceid>FETCH-LOGICAL-c237t-2365f9814edfea7c27269e6f13da6e67482d44f8f6e3e93ab7489ae74921d2f3</originalsourceid><addsrcrecordid>eNp9kcuOFCEUhonROO3oC7gwLN1UyaUKGuNm0vGWTGJij24JA4dpOlXQAjXJPImvK5UeXboige_85Ds_Qq8p6Smh4t2xN8dge0bY0BPZE0qeoA0dmew4U-Ip2hCqRCfGkV-gF6UcCSGKi_E5uuCKjHykfIN-76--77td-tkxXJZ8D2GaTLSAK5Qa4h020eFQ0mRqSBHPJpo7mCFWnDwO87zEZNN8ymkOBRw-Naw9lvd4v4Y94AxlmWrBvhGYcnwAM9UDtiYDto2EXHCIuB4A_4ihtoh9Ne3vl-iZN1OBV4_nJbr59PFm96W7_vb56-7qurOMy9qx5uPVlg7gPBhpmWRCgfCUOyNAyGHL3DD4rRfAQXFz226UATkoRh3z_BK9Pcc2g19LU9bNw8K6A0hL0ZxsBykZlbKh7IzanErJ4PUph9nkB02JXvvQR732odc-NJG69dGG3jzmL7czuH8jfwtowIczAE3yPkDWxbYNWnAhg63apfC__D_pOp48</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3084772177</pqid></control><display><type>article</type><title>SARS-CoV-2 surveillance testing and isolation management of immunocompromised patients: Survey results from 13 health care centers in the United States</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Aslam, Anoshé ; Kamboj, Mini ; Bubb, Tania</creator><creatorcontrib>Aslam, Anoshé ; Kamboj, Mini ; Bubb, Tania</creatorcontrib><description>As a newly emerging pathogen, infection prevention and isolation management response for SARS-CoV-2 varied greatly by individual health care center. Specific patient population needs, especially those of severely immunocompromised oncologic patients, potentially intensified the response. A survey was distributed to academic health care centers to ascertain surveillance testing frequency, patient placement, and isolation management for patients undergoing cell therapy treatments.
•Current SARS-CoV-2 guidance lacks information for patients receiving HCTs.•A survey sent to 13 transplant centers revealed heterogeneity in application of guidance.•Despite differences, transmission events were not reported.</description><identifier>ISSN: 0196-6553</identifier><identifier>ISSN: 1527-3296</identifier><identifier>EISSN: 1527-3296</identifier><identifier>DOI: 10.1016/j.ajic.2024.07.010</identifier><identifier>PMID: 39053513</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>COVID-19 - epidemiology ; COVID-19 - prevention & control ; COVID-19 Testing - methods ; Health Facilities - statistics & numerical data ; Humans ; Immunocompromised Host ; Infection Control - methods ; Infection prevention ; Oncology ; Patient Isolation ; Positive pressure ; SARS-CoV-2 - immunology ; Surveys and Questionnaires ; United States</subject><ispartof>American journal of infection control, 2024-12, Vol.52 (12), p.1463-1465</ispartof><rights>2024 Association for Professionals in Infection Control and Epidemiology, Inc.</rights><rights>Copyright © 2024 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c237t-2365f9814edfea7c27269e6f13da6e67482d44f8f6e3e93ab7489ae74921d2f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ajic.2024.07.010$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3548,27923,27924,45994</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39053513$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aslam, Anoshé</creatorcontrib><creatorcontrib>Kamboj, Mini</creatorcontrib><creatorcontrib>Bubb, Tania</creatorcontrib><title>SARS-CoV-2 surveillance testing and isolation management of immunocompromised patients: Survey results from 13 health care centers in the United States</title><title>American journal of infection control</title><addtitle>Am J Infect Control</addtitle><description>As a newly emerging pathogen, infection prevention and isolation management response for SARS-CoV-2 varied greatly by individual health care center. Specific patient population needs, especially those of severely immunocompromised oncologic patients, potentially intensified the response. A survey was distributed to academic health care centers to ascertain surveillance testing frequency, patient placement, and isolation management for patients undergoing cell therapy treatments.
•Current SARS-CoV-2 guidance lacks information for patients receiving HCTs.•A survey sent to 13 transplant centers revealed heterogeneity in application of guidance.•Despite differences, transmission events were not reported.</description><subject>COVID-19 - epidemiology</subject><subject>COVID-19 - prevention & control</subject><subject>COVID-19 Testing - methods</subject><subject>Health Facilities - statistics & numerical data</subject><subject>Humans</subject><subject>Immunocompromised Host</subject><subject>Infection Control - methods</subject><subject>Infection prevention</subject><subject>Oncology</subject><subject>Patient Isolation</subject><subject>Positive pressure</subject><subject>SARS-CoV-2 - immunology</subject><subject>Surveys and Questionnaires</subject><subject>United States</subject><issn>0196-6553</issn><issn>1527-3296</issn><issn>1527-3296</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcuOFCEUhonROO3oC7gwLN1UyaUKGuNm0vGWTGJij24JA4dpOlXQAjXJPImvK5UeXboige_85Ds_Qq8p6Smh4t2xN8dge0bY0BPZE0qeoA0dmew4U-Ip2hCqRCfGkV-gF6UcCSGKi_E5uuCKjHykfIN-76--77td-tkxXJZ8D2GaTLSAK5Qa4h020eFQ0mRqSBHPJpo7mCFWnDwO87zEZNN8ymkOBRw-Naw9lvd4v4Y94AxlmWrBvhGYcnwAM9UDtiYDto2EXHCIuB4A_4ihtoh9Ne3vl-iZN1OBV4_nJbr59PFm96W7_vb56-7qurOMy9qx5uPVlg7gPBhpmWRCgfCUOyNAyGHL3DD4rRfAQXFz226UATkoRh3z_BK9Pcc2g19LU9bNw8K6A0hL0ZxsBykZlbKh7IzanErJ4PUph9nkB02JXvvQR732odc-NJG69dGG3jzmL7czuH8jfwtowIczAE3yPkDWxbYNWnAhg63apfC__D_pOp48</recordid><startdate>202412</startdate><enddate>202412</enddate><creator>Aslam, Anoshé</creator><creator>Kamboj, Mini</creator><creator>Bubb, Tania</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202412</creationdate><title>SARS-CoV-2 surveillance testing and isolation management of immunocompromised patients: Survey results from 13 health care centers in the United States</title><author>Aslam, Anoshé ; Kamboj, Mini ; Bubb, Tania</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c237t-2365f9814edfea7c27269e6f13da6e67482d44f8f6e3e93ab7489ae74921d2f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>COVID-19 - epidemiology</topic><topic>COVID-19 - prevention & control</topic><topic>COVID-19 Testing - methods</topic><topic>Health Facilities - statistics & numerical data</topic><topic>Humans</topic><topic>Immunocompromised Host</topic><topic>Infection Control - methods</topic><topic>Infection prevention</topic><topic>Oncology</topic><topic>Patient Isolation</topic><topic>Positive pressure</topic><topic>SARS-CoV-2 - immunology</topic><topic>Surveys and Questionnaires</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aslam, Anoshé</creatorcontrib><creatorcontrib>Kamboj, Mini</creatorcontrib><creatorcontrib>Bubb, Tania</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of infection control</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aslam, Anoshé</au><au>Kamboj, Mini</au><au>Bubb, Tania</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>SARS-CoV-2 surveillance testing and isolation management of immunocompromised patients: Survey results from 13 health care centers in the United States</atitle><jtitle>American journal of infection control</jtitle><addtitle>Am J Infect Control</addtitle><date>2024-12</date><risdate>2024</risdate><volume>52</volume><issue>12</issue><spage>1463</spage><epage>1465</epage><pages>1463-1465</pages><issn>0196-6553</issn><issn>1527-3296</issn><eissn>1527-3296</eissn><abstract>As a newly emerging pathogen, infection prevention and isolation management response for SARS-CoV-2 varied greatly by individual health care center. Specific patient population needs, especially those of severely immunocompromised oncologic patients, potentially intensified the response. A survey was distributed to academic health care centers to ascertain surveillance testing frequency, patient placement, and isolation management for patients undergoing cell therapy treatments.
•Current SARS-CoV-2 guidance lacks information for patients receiving HCTs.•A survey sent to 13 transplant centers revealed heterogeneity in application of guidance.•Despite differences, transmission events were not reported.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>39053513</pmid><doi>10.1016/j.ajic.2024.07.010</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0196-6553 |
| ispartof | American journal of infection control, 2024-12, Vol.52 (12), p.1463-1465 |
| issn | 0196-6553 1527-3296 1527-3296 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3084772177 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | COVID-19 - epidemiology COVID-19 - prevention & control COVID-19 Testing - methods Health Facilities - statistics & numerical data Humans Immunocompromised Host Infection Control - methods Infection prevention Oncology Patient Isolation Positive pressure SARS-CoV-2 - immunology Surveys and Questionnaires United States |
| title | SARS-CoV-2 surveillance testing and isolation management of immunocompromised patients: Survey results from 13 health care centers in the United States |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-12T04%3A56%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=SARS-CoV-2%20surveillance%20testing%20and%20isolation%20management%20of%20immunocompromised%20patients:%20Survey%20results%20from%2013%20health%20care%20centers%20in%20the%20United%20States&rft.jtitle=American%20journal%20of%20infection%20control&rft.au=Aslam,%20Anosh%C3%A9&rft.date=2024-12&rft.volume=52&rft.issue=12&rft.spage=1463&rft.epage=1465&rft.pages=1463-1465&rft.issn=0196-6553&rft.eissn=1527-3296&rft_id=info:doi/10.1016/j.ajic.2024.07.010&rft_dat=%3Cproquest_cross%3E3084772177%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3084772177&rft_id=info:pmid/39053513&rft_els_id=S0196655324006102&rfr_iscdi=true |